-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Amarin (NASDAQ:AMRN) Trading 5.8% Higher
Amarin (NASDAQ:AMRN) Trading 5.8% Higher
Amarin Co. plc (NASDAQ:AMRN – Get Rating) shares traded up 5.8% during trading on Tuesday . The stock traded as high as $1.29 and last traded at $1.28. 161,179 shares changed hands during mid-day trading, a decline of 96% from the average session volume of 3,916,424 shares. The stock had previously closed at $1.21.
Analysts Set New Price Targets
Several analysts have commented on the company. The Goldman Sachs Group lowered their price target on Amarin from $1.75 to $1.50 and set a "sell" rating for the company in a report on Tuesday, May 24th. StockNews.com upgraded Amarin from a "sell" rating to a "hold" rating in a report on Wednesday, July 27th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $2.50.
Get Amarin alerts:Amarin Stock Performance
The stock has a market cap of $520.14 million, a PE ratio of -4.86 and a beta of 1.87. The stock has a fifty day simple moving average of $1.44 and a two-hundred day simple moving average of $2.16.
Amarin (NASDAQ:AMRN – Get Rating) last released its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.05). The company had revenue of $94.44 million during the quarter, compared to analysts' expectations of $88.21 million. Amarin had a negative return on equity of 13.63% and a negative net margin of 21.05%. The firm's revenue was down 38.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.02 EPS. On average, equities analysts predict that Amarin Co. plc will post -0.36 EPS for the current fiscal year.Insider Activity
In other news, Director Olsen Per Wold acquired 55,000 shares of Amarin stock in a transaction that occurred on Monday, June 13th. The shares were purchased at an average cost of $1.69 per share, for a total transaction of $92,950.00. Following the completion of the purchase, the director now directly owns 149,000 shares of the company's stock, valued at approximately $251,810. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.90% of the company's stock.
Institutional Investors Weigh In On Amarin
A number of hedge funds have recently added to or reduced their stakes in AMRN. Creative Planning lifted its stake in Amarin by 66.4% in the second quarter. Creative Planning now owns 17,285 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 6,900 shares during the last quarter. UMB Bank N A MO bought a new stake in Amarin in the fourth quarter valued at $28,000. Quantbot Technologies LP bought a new stake in Amarin in the first quarter valued at $31,000. Masso Torrence Wealth Management Inc. bought a new stake in Amarin in the fourth quarter valued at $34,000. Finally, Winthrop Advisory Group LLC bought a new stake in Amarin in the first quarter valued at $34,000. 34.15% of the stock is currently owned by institutional investors.
About Amarin
(Get Rating)
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Read More
- Get a free copy of the StockNews.com research report on Amarin (AMRN)
- Broadcom Bounces From Institutional Bottom
- Is Autozone A Buy Before Earnings Are Released?
- Affirm is the Underdog Starring in a Spaghetti Western
- Is There Value in Verizon Shares at These Levels?
- MarketBeat Podcast: Stock Market, Bad News is Good News
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.
Amarin Co. plc (NASDAQ:AMRN – Get Rating) shares traded up 5.8% during trading on Tuesday . The stock traded as high as $1.29 and last traded at $1.28. 161,179 shares changed hands during mid-day trading, a decline of 96% from the average session volume of 3,916,424 shares. The stock had previously closed at $1.21.
纳斯达克的股价在周二的交易中上涨了5.8%。该股一度涨至1.29美元,最后报1.28美元。午盘交易中,161,179股易手,较3916,424股的平均成交量下降了96%。该股此前收盘价为1.21美元。
Analysts Set New Price Targets
分析师设定新的价格目标
Several analysts have commented on the company. The Goldman Sachs Group lowered their price target on Amarin from $1.75 to $1.50 and set a "sell" rating for the company in a report on Tuesday, May 24th. StockNews.com upgraded Amarin from a "sell" rating to a "hold" rating in a report on Wednesday, July 27th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $2.50.
几位分析师对该公司发表了评论。高盛夫妇在5月24日周二的一份报告中将Amarin的目标价从1.75美元下调至1.5美元,并对该公司设定了“卖出”评级。在7月27日周三的一份报告中,StockNews.com将Amarin的评级从“卖出”上调至“持有”。两名股票研究分析师对该股的评级为卖出,四名分析师给予该股持有评级,一名分析师给予该股买入评级。根据MarketBeat的数据,该公司的共识评级为持有,共识目标价为2.50美元。
Amarin Stock Performance
Amarin股票表现
The stock has a market cap of $520.14 million, a PE ratio of -4.86 and a beta of 1.87. The stock has a fifty day simple moving average of $1.44 and a two-hundred day simple moving average of $2.16.
该股市值为5.2014亿美元,市盈率为-4.86倍,贝塔系数为1.87。该股的50日简单移动均线为1.44美元,200日简单移动均线为2.16美元。
Insider Activity
内幕活动
In other news, Director Olsen Per Wold acquired 55,000 shares of Amarin stock in a transaction that occurred on Monday, June 13th. The shares were purchased at an average cost of $1.69 per share, for a total transaction of $92,950.00. Following the completion of the purchase, the director now directly owns 149,000 shares of the company's stock, valued at approximately $251,810. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.90% of the company's stock.
在其他新闻方面,董事奥尔森在6月13日(星期一)的一笔交易中收购了55,000股Amarin股票。这些股票是以每股1.69美元的平均成本购买的,总交易额为92,950.00美元。收购完成后,董事现在直接拥有14.9万股该公司股票,价值约251,810美元。这笔交易是在提交给美国证券交易委员会(Securities&Exchange Commission)的一份文件中披露的,可以通过这个超级链接访问。公司内部人士持有该公司0.90%的股份。
Institutional Investors Weigh In On Amarin
机构投资者看好Amarin
A number of hedge funds have recently added to or reduced their stakes in AMRN. Creative Planning lifted its stake in Amarin by 66.4% in the second quarter. Creative Planning now owns 17,285 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 6,900 shares during the last quarter. UMB Bank N A MO bought a new stake in Amarin in the fourth quarter valued at $28,000. Quantbot Technologies LP bought a new stake in Amarin in the first quarter valued at $31,000. Masso Torrence Wealth Management Inc. bought a new stake in Amarin in the fourth quarter valued at $34,000. Finally, Winthrop Advisory Group LLC bought a new stake in Amarin in the first quarter valued at $34,000. 34.15% of the stock is currently owned by institutional investors.
一些对冲基金最近增持或减持了amrn的股份。创意策划在第二季度增持了66.4%的Amarin股份。Creative Planning现在拥有这家生物制药公司17,285股股票,价值26,000美元,上个季度又购买了6,900股。UMB Bank N A MO在第四季度购买了Amarin的新股份,价值2.8万美元。Quantbot Technologies LP在第一季度购买了Amarin的新股份,价值3.1万美元。马索·托伦斯财富管理公司去年第四季度以3.4万美元的价格购入了Amarin的新股份。最后,Winthrop Consulting Group LLC在第一季度购买了Amarin的新股份,价值3.4万美元。34.15%的股票目前由机构投资者持有。
About Amarin
关于阿玛林
(Get Rating)
(获取评级)
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Amarin Corporation plc是一家制药公司,在美国、德国、加拿大、黎巴嫩和阿拉伯联合酋长国从事心血管疾病治疗药物的开发和商业化。它的主要产品是Vascepa,一种仅限处方的omega-3脂肪酸产品,用作饮食的辅助产品,用于降低患有严重高甘油三酯血症的成年患者的甘油三酯水平。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Amarin (AMRN)
- Broadcom Bounces From Institutional Bottom
- Is Autozone A Buy Before Earnings Are Released?
- Affirm is the Underdog Starring in a Spaghetti Western
- Is There Value in Verizon Shares at These Levels?
- MarketBeat Podcast: Stock Market, Bad News is Good News
- 免费获取StockNews.com关于Amarin的研究报告(Amrn)
- 博通从机构底部反弹
- AutoZone是在收益发布之前买入的吗?
- 阿奎姆是意大利西部片中的失败者
- 在这些水平上,Verizon的股价有价值吗?
- 市场Beat播客:股市,坏消息就是好消息
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.
接受《阿马林日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Amarin和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧